Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Bitcoin Trust — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.32 (market cap $8.04B), while iShares Bitcoin Trust trades at $36.87. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| BIO | IBIT | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Crypto-linked |
52-Week High | $339.75 | $71.29 |
52-Week Low | $241.71 | $33.29 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
IBIT trades at $35.22, down 2.79% today, reflecting recent bearish pressure. Technical indicators show a predominantly bearish trend with moving averages signaling sell conditions, while oscillators remain neutral. The stock faces resistance at $36 and finds support at $35. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing competitors like Fidelity's offering as of June 29, 2026 (The Motley Fool).
The outlook for IBIT hinges on Bitcoin ETF flows and market sentiment toward crypto assets. Investment opportunities include its dominant market share and low expense ratio, but risks involve significant outflows from Bitcoin ETFs, with a record $4.5 billion in June 2026 (Zacks Investment Research, July 6, 2026), and volatility linked to cryptocurrency price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
